Xyotax (CT-2103) : Cell Therapeutics, Inc. : Paclitaxel conjugate

Pivotal Trials Demonstrate Xyotax Produces Equivalent Survival While Reducing Serious Side Effects in the Treatment of NSCLC (Cell Therapeutics, Inc.)
Press release announcing the results of two phase III trials in NSCLC designed to determine if Xyotax could increase the overall survival of patients while reducing the serious side effects associated with the treatment of first-line or second-line NSCLC. Both trials demonstrated equivalent survival with significant reductions in serious side effects when compared to either docetaxel or gemcitabine/vinorelbine; although they missed their primary endpoints of superior overall survival. Xyotax is administered in a 10-minute infusion without the need for steroids or other premedications. [5/05]

Xyotax (CT-2103) - Recent MEDLINE Abstracts (PubMed)

Xyotax (CT-2103) - Clinical Trials (ClinicalTrials.gov)